Scot Roberts - Altimmune Chief Scientific Officer
| ALT Stock | USD 8.25 0.07 0.86% |
Executive
Dr. M. Scot Roberts, Ph.D. is Chief Scientific Officer of the Company. Dr. Roberts currently serves as Chief Scientific Officer of the Company. Dr. Roberts joined Altimmune in December 2012 and has nearly 20 years of senior technical leadership experience, most recently at ImQuest BioSciences, Inc., where as Chief Scientific Officer from November 2010 until November 2012, he was responsible for managing scientific operations as well as business development opportunities in cancer and antivirals. Dr. Roberts held key positions at Wellstat Biologics Corporation from August 1996 until October 2010, including Director of Research and Development where he was responsible for a portfolio of biologic candidates in oncology including a clinical stage asset. He also led bioassay development efforts for the company and assumed leadership roles in upstream process development and animal pharmacology while at Wellstat. Dr. Roberts has significant experience in both small molecule and biologics drug development with a focus on viral vectors and antiviral therapies. Dr. Roberts completed a postdoctoral fellowship at the National Cancer Institute, Laboratory of Molecular Virology and has numerous patents and publications in peerreviewed journals, and was an invited speaker and Chair at numerous international conferences since 2017.
| Age | 65 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | 910 Clopper Road, Gaithersburg, MD, United States, 20878 |
| Phone | 240 654 1450 |
| Web | https://altimmune.com |
Altimmune Management Efficiency
The company has Return on Asset of (0.3956) % which means that on every $100 spent on assets, it lost $0.3956. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7296) %, meaning that it generated no profit with money invested by stockholders. Altimmune's management efficiency ratios could be used to measure how well Altimmune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.51 in 2024. Total Current Liabilities is likely to gain to about 21.2 M in 2024. Liabilities And Stockholders Equity is likely to gain to about 221.2 M in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Sanjeev MD | ACADIA Pharmaceuticals | N/A | |
| Mark JD | Athira Pharma | 58 | |
| David JD | Akero Therapeutics | N/A | |
| Geoffrey Barker | Viking Therapeutics | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Scott Gangloff | Akero Therapeutics | 50 | |
| George Thornton | Cassava Sciences | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Stephanie Kim | ACADIA Pharmaceuticals | N/A | |
| Douglas MD | ACADIA Pharmaceuticals | 62 | |
| Michael Zamloot | Cassava Sciences | N/A | |
| Rob Ackles | ACADIA Pharmaceuticals | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
| Robyn Hunter | Fortress Biotech | 62 | |
| Lisa Buffington | Verastem | N/A | |
Management Performance
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.4 |
Altimmune Leadership Team
Elected by the shareholders, the Altimmune's board of directors comprises two types of representatives: Altimmune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Altimmune. The board's role is to monitor Altimmune's management team and ensure that shareholders' interests are well served. Altimmune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Altimmune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scot Roberts, Chief Scientific Officer | ||
| Tony BS, Vice Management | ||
| Vipin Garg, President CEO, Director | ||
| Richard MBA, Chief Officer | ||
| Kent BSEE, Co Controller | ||
| Andrew MS, Corporate Controller | ||
| Bertrand Georges, Chief Officer | ||
| Raymond MBA, Chief Officer | ||
| Jos Ochoa, Chief Officer | ||
| AGAF FCAP, Chief Officer |
Altimmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Altimmune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 450.24 M | ||||
| Shares Outstanding | 71.12 M | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 56.67 % | ||||
| Number Of Shares Shorted | 23.43 M | ||||
| Price To Earning | (1.66) X | ||||
| Price To Book | 4.41 X | ||||
| Price To Sales | 11,284 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.